Development and Evaluation of Peptide-Targeted Liposomal Nanoparticle System for Selective Drug Delivery and Combination Therapy in Multiple Myeloma and Lung Cancer

Multiple myeloma (MM) and lung cancer are clinically challenging malignancies, characterized by therapeutic resistance and poor long-term outcomes in advanced stages. Although significant progress has been made through conventional chemotherapy, immunotherapy, and early-generation targeted approaches, these treatments often face limitations related to off-target toxicity, drug delivery efficiency, and the ability to overcome tumor heterogeneity. To address these challenges, this dissertation investigates the development and application of peptide-targeted liposomal nanoparticles as an advanced drug delivery platform. Through a series of in vitro and in vivo studies, novel peptide ligands were rationally designed and incorporated into nanoparticle systems to achieve selective tumor targeting, enhance cellular uptake, and optimize biodistribution. The therapeutic potential of these systems was evaluated using various anticancer modalities, including prodrug formulations, immunogenic cell death induces, the co-delivery of siRNA with chemotherapeutic agents, and combinational drug treatments, demonstrating synergistic anticancer effects in relevant preclinical models of MM and lung cancer. Collectively, the findings highlight the promise of peptide-targeted liposomal nanoparticles as a versatile and effective strategy to improve drug delivery precision and therapeutic efficacy in these malignancies. Integration of such advanced targeted therapies with personalized medicine approaches and biomarker-driven patient selection may further enhance treatment outcomes, overcome resistance mechanisms, and contribute to the evolution of next-generation cancer therapeutics.<p></p>